Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Examining Th-17 Mediated Inflammation as a Mechanism for Transporter Dysregulation in Pregnant Lupus Patients
EF 2021-22
Résumé
Systemic lupus erythematosus (SLE) is an autoimmune disease (AD) that mainly affects women of child-bearing age and can cause poor pregnancy outcomes. SLE is often treated with immunosuppressants, so it is important that the integrity of protective transporter expression is maintained during pregnancy to avoid toxic drug accumulation while still treating the patient. However, research from our lab has demonstrated that important protective transporters are dysregulated in SLE placenta; additionally, Th17 cytokines are upregulated in patient serum at term. Another study showed, independent of disease, that treatment of healthy explants with Th17 cytokines can impart similar changes on transporter expression. Therefore, we postulate that the observed upregulation of Th17-cytokines in SLE could be responsible for the observed changes in disease transporter expression. Here we propose to examine the factors that cause dysregulation of transporters in SLE patients, focusing on Th17-mediated inflammation as a driver. Placenta from healthy patients will be collected for primary culture explant work and treated with individual and combination Th17 cytokines at physiologically relevant concentrations. mRNA and protein expression of transporters and immune mediators will be determined at both a targeted and global level to confirm the relationship between Th17 levels and expression, as well as identify other affected factors on a holistic level. The second phase will involve the same process, this time with SLE affected term placenta. Potentially, other mechanistic studies in relevant cells may follow using inhibitors of key Th17 pathways. This research will help shape our understanding of drug safety in pregnant women with AD, and improve our suggestions for effective therapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466578
Name
Pollinzi Angela
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Examining Th-17 Mediated Inflammation as a Mechanism for Transporter Dysregulation in Pregnant Lupus Patients
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoimmune Disease; Drug Transporters; Inflammation; Maternal-Fetal Health; Pharmaceutical Science; Placenta; Pregnancy; Systemic Lupus Erythematosus
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease (AD) that mainly affects women of child-bearing age and can cause poor pregnancy outcomes. SLE is often treated with immunosuppressants, so it is important that the integrity of protective transporter expression is maintained during pregnancy to avoid toxic drug accumulation while still treating the patient. However, research from our lab has demonstrated that important protective transporters are dysregulated in SLE placenta; additionally, Th17 cytokines are upregulated in patient serum at term. Another study showed, independent of disease, that treatment of healthy explants with Th17 cytokines can impart similar changes on transporter expression. Therefore, we postulate that the observed upregulation of Th17-cytokines in SLE could be responsible for the observed changes in disease transporter expression. Here we propose to examine the factors that cause dysregulation of transporters in SLE patients, focusing on Th17-mediated inflammation as a driver. Placenta from healthy patients will be collected for primary culture explant work and treated with individual and combination Th17 cytokines at physiologically relevant concentrations. mRNA and protein expression of transporters and immune mediators will be determined at both a targeted and global level to confirm the relationship between Th17 levels and expression, as well as identify other affected factors on a holistic level. The second phase will involve the same process, this time with SLE affected term placenta. Potentially, other mechanistic studies in relevant cells may follow using inhibitors of key Th17 pathways. This research will help shape our understanding of drug safety in pregnant women with AD, and improve our suggestions for effective therapy.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pollinzi, Angela
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~